| Updated:
Goldshield harmed by bid battle
The chairman of Goldshield has admitted that the takeover battle for the pharmaceutical group has harmed its performance. Dr Keith Hallawell said investment in new products had stalled due to the uncertainty that the bid battle created among suppliers.
Goldshield’s management team has agreed to aqcuire the company for £179m after gaining the support of shareholders and outbidding rival AIT Investments.